Stoke Therapeutics, Inc. reported $28M of revenue over the trailing twelve months, −86% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $28M (to Q2 2026). Net income: −$208M, trailing twelve months to Q2 2026. Free cash flow: −$181M, trailing twelve months to Q2 2026. Operating margin: −1587%, trailing twelve months to Q2 2026.

STOKStoke Therapeutics, Inc.

Healthcare

$24.71+7.9% 1Y

$24.71

$22.3752 weeks$38.35

STOK as reported

Stoke Therapeutics, Inc. reported $28M of revenue over the trailing twelve months, −86% on the year before. 8 reported series are charted on this page, each one as filed.

$28M

Revenue, trailing twelve months · to Q2 2026 · −86% against the twelve months before

Net income: −$208M
Net income · −496% year on year · trailing twelve months to Q2 2026
Free cash flow: −$181M
Free cash flow · −395% year on year · trailing twelve months to Q2 2026
Operating margin: −1587%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for STOK, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$28M	−86%	Q2 2026
Net income	−$208M	−496%	Q2 2026
EPS	−$3.34	−488%	Q2 2026
Operating margin	−1587%	n/a	Q2 2026
Net margin	−1489%	n/a	Q2 2026
ROE	−23%	n/a	Q2 2026
ROA	−20%	n/a	Q2 2026
Free cash flow	−$181M	−395%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.